Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-8.56 Insider Own5.10% Shs Outstand56.72M Perf Week20.64%
Market Cap7.49B Forward P/E- EPS next Y-6.12 Insider Trans0.28% Shs Float- Perf Month30.74%
Income-620.30M PEG- EPS next Q-1.85 Inst Own99.30% Short Float- Perf Quarter51.75%
Sales365.10M P/S20.51 EPS this Y-533.90% Inst Trans4.71% Short Ratio11.14 Perf Half Y3.92%
Book/sh13.42 P/B9.84 EPS next Y21.50% ROA-35.20% Target Price183.09 Perf Year8.22%
Cash/sh18.49 P/C7.14 EPS next 5Y-0.20% ROE-55.40% 52W Range72.05 - 158.80 Perf YTD21.00%
Dividend- P/FCF- EPS past 5Y-10.60% ROI-23.60% 52W High-16.85% Beta2.24
Dividend %- Quick Ratio5.50 Sales past 5Y84.10% Gross Margin85.20% 52W Low83.28% ATR6.35
Employees499 Current Ratio6.30 Sales Q/Q26.10% Oper. Margin- RSI (14)76.17 Volatility5.30% 3.69%
OptionableYes Debt/Eq0.00 EPS Q/Q-47.60% Profit Margin- Rel Volume8.17 Prev Close100.47
ShortableYes LT Debt/Eq0.44 EarningsNov 07 AMC Payout- Avg Volume1.32M Price132.05
Recom1.70 SMA2025.26% SMA5039.35% SMA20015.70% Volume10,767,851 Change31.43%
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-13-19 04:11PM  Sarepta Rockets On Stunning Reversal For Previously Rejected Drug Investor's Business Daily +31.43%
12:22PM  Sareptas surprise FDA approval for rare disease drug excites investors MarketWatch
10:13AM  FDA approves Sarepta's muscular dystrophy drug Yahoo Finance Video
09:00AM  Sarepta Stock Is Spiking as FDA Reverses Course, Approving Drug Barrons.com
08:55AM  Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up Zacks
08:30AM  Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing GlobeNewswire
08:10AM  The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer Benzinga
04:36AM  Sarepta Therapeutics Surges on FDA Approval of Muscular Dystrophy Treatment TheStreet.com
Dec-12-19 09:28PM  In an about face, FDA approves Sarepta's 2nd Duchenne drug American City Business Journals
06:43PM  Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drug MarketWatch
06:19PM  Sarepta Therapeutics Announces FDA Approval of VYONDYS 53 (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 GlobeNewswire
Dec-10-19 09:21AM  Why Is Sarepta Therapeutics (SRPT) Up 17.2% Since Last Earnings Report? Zacks
07:00AM  Biotech accelerator teams with investment firm for $210M fund raise American City Business Journals
Dec-06-19 09:33AM  The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics Zacks
Dec-05-19 04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
09:37AM  4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
Dec-04-19 08:33PM  Did Hedge Funds Drop The Ball On Sarepta Therapeutics Inc (SRPT) ? Insider Monkey
Dec-03-19 11:53AM  The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga
10:19AM  Breakeven On The Horizon For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Simply Wall St.
Nov-29-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-26-19 12:20PM  Why Did Farallon Capital Get Out of These 3 Biotech Stocks? TipRanks
Nov-15-19 08:57AM  Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal Zacks
Nov-14-19 04:15PM  This Biotech Stock Just Slumped On A $48 Million Gene-Therapy Deal Investor's Business Daily
01:27PM  Sarepta expands gene therapy push with $90M deal American City Business Journals
08:30AM  Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies GlobeNewswire
Nov-13-19 03:39AM  Edited Transcript of SRPT earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 04:03PM  Biotech Pops After Rival's Gene Therapy Halted By Regulators Investor's Business Daily +5.45%
02:44PM  3 Stocks That Wall Street Thinks Could Rise 40% or More TipRanks
10:56AM  FDA intervenes for 3rd time in Solid Biosciences' Duchenne drug tests American City Business Journals
Nov-08-19 02:33PM  Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
09:45AM  Sareptas Earnings Show Promise, Analysts Say, but the Stock Is Flat Barrons.com
Nov-07-19 06:28PM  Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM  Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Nov-05-19 04:30PM  Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference GlobeNewswire
Oct-31-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
10:34AM  Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline Zacks
Oct-29-19 10:55AM  CLASS ACTION UPDATE for SRPT, MTCH and INFY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:09AM  FINAL DEADLINE ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
Oct-28-19 10:45AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRPT, SNDL and TME ACCESSWIRE
09:31AM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
08:50AM  FINAL DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Oct-25-19 04:15PM  CLASS ACTION UPDATE for SRPT, MDP and CC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
03:00PM  DEADLINE ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: October 29, 2019 GlobeNewswire
01:15PM  SHAREHOLDER ALERT: SRPT MTCH CC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
01:03PM  SAREPTA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
01:01PM  Are Insiders Buying Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock? Simply Wall St.
12:16PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:20AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRPT, OLLI and CC ACCESSWIRE
09:50AM  FINAL DEADLINE ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
Oct-24-19 04:30PM  Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019 GlobeNewswire
11:47AM  How to invest in biotech stocks like a Nobel Prize winner MarketWatch
10:06AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRPT, VRAY, MTCH and TME GlobeNewswire
Oct-23-19 10:03PM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
08:55PM  6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
07:40PM  SAREPTA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Business Wire
09:50AM  DEADLINE ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
Oct-22-19 10:45AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRPT, TME and CVET ACCESSWIRE
10:00AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Oct-21-19 08:03PM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
07:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
07:40PM  SHAREHOLDER ALERT: SRPT MYGN CC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
06:50PM  OCTOBER 29 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
06:47PM  3 Stocks That Gurus, Insiders and Companies Are Buying GuruFocus.com
Oct-18-19 03:30PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRPT, TME and UBER ACCESSWIRE
03:00PM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions GlobeNewswire
11:15AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SRPT, MGNX and TME ACCESSWIRE
10:37AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions ACCESSWIRE
Oct-17-19 02:45PM  CLASS ACTION UPDATE for SRPT, MO and MYGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
02:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
Oct-16-19 07:30PM  SHAREHOLDER ALERT: SRPT MTCH WTRH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
05:31PM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
05:04PM  OCTOBER 29 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
01:45PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SRPT, MDP and TME ACCESSWIRE
10:36AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions ACCESSWIRE
10:32AM  Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline Zacks
09:30AM  CLASS ACTION UPDATE for COF, SRPT, CADE and WTRH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Oct-15-19 08:37PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Valaris, Sarepta Therapeutics, Canada Goose, and Meredith Corporation and Encourages Investors to Contact the Firm GlobeNewswire
04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
Oct-14-19 10:16AM  The Biotech Sector Is Lagging. Blame Gene Therapy Stocks, Analysts Say. Barrons.com
Oct-12-19 02:22PM  Hedge Funds Have Never Been This Bullish On Sarepta Therapeutics Inc (SRPT) Insider Monkey
Oct-11-19 06:50PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRPT, TXT and TME ACCESSWIRE
05:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
03:35PM  CLASS ACTION UPDATE for SRPT, MGNX and CADE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
03:00PM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions GlobeNewswire
11:05AM  SHAREHOLDER ALERT: SRPT DBX TME: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:35AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Class Action - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Oct-10-19 11:05AM  CLASS ACTION UPDATE for CVS, SRPT and DBX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:34AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Oct-09-19 10:45AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRPT, MGNX and UBER ACCESSWIRE
08:00AM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm GlobeNewswire
Oct-08-19 12:33PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
09:43AM  CLASS ACTION UPDATE for PS, IFF, SRPT and SNDL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
08:03AM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
Oct-07-19 11:00AM  SHAREHOLDER ALERT: SRPT VRAY CADE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE -8.26%
10:33AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
08:48AM  Company News For Oct 7, 2019 Zacks
Oct-04-19 04:30PM  Does This Beleaguered Biotech Stock Have A Winner In Gene Therapy? Investor's Business Daily +8.50%
10:19AM  Sarepta Climbs as Gene Therapy Shows Promise in Early Study Bloomberg
09:29AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TWOU, SRPT, SNDL and MGNX GlobeNewswire
08:31AM  Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy GlobeNewswire
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Howton David TEVP, General CounselNov 22Option Exercise16.1334,272552,66736,993Nov 26 08:01 PM
Howton David TEVP, General CounselNov 22Sale105.0025,0002,625,00011,993Nov 26 08:01 PM
Barry RichardDirectorSep 13Buy87.493,309289,5043,187,065Sep 16 08:00 AM
Barry RichardDirectorSep 12Buy87.491,691147,9503,183,756Sep 16 08:00 AM
BONNEY MICHAEL WDirectorSep 09Buy86.742,000173,4807,051Sep 09 02:18 PM
BEHRENS M KATHLEENDirectorSep 06Buy87.982,500219,950125,667Sep 06 02:13 PM
BEHRENS M KATHLEENDirectorSep 05Option Exercise7.805,00039,000123,167Sep 06 02:13 PM
Mahatme SandeshEVP, CFO & CBOAug 21Option Exercise23.85100,0002,385,000130,179Aug 22 07:20 PM
Barry RichardDirectorAug 20Buy99.325,000496,5933,182,065Aug 20 05:43 PM
Mahatme SandeshEVP, CFO & CBOAug 15Option Exercise24.739,754241,23230,179Aug 15 04:33 PM
Barry RichardDirectorAug 14Buy122.503,700453,2503,177,065Aug 14 04:38 PM
Barry RichardDirectorAug 12Buy122.501,300159,2503,173,365Aug 13 04:31 PM
INGRAM DOUGLAS SPresident & CEOAug 12Buy123.0716,2522,000,160432,197Aug 12 05:48 PM
Wigzell Hans Lennart RudolfDirectorMay 23Option Exercise7.8010,00078,00021,717May 24 08:03 PM
Wigzell Hans Lennart RudolfDirectorMay 23Sale120.0010,0001,200,00011,717May 24 08:03 PM
Mahatme SandeshEVP, CFO & CBOMar 19Option Exercise21.4615,486332,30819,354Mar 20 08:00 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Option Exercise23.8565,0001,550,25073,649Feb 08 08:02 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Sale145.0065,0009,425,0008,649Feb 08 08:02 PM
Howton David TSVP, General CounselFeb 01Option Exercise21.6521,500465,39149,571Feb 01 08:25 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Option Exercise22.547,500169,03530,266Feb 01 08:27 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Sale140.0015,0002,100,00015,266Feb 01 08:27 PM
Howton David TSVP, General CounselFeb 01Sale140.0030,0004,200,00019,571Feb 01 08:25 PM
Mahatme SandeshEVP, CFO & CBOJan 31Option Exercise23.8521,198505,57229,847Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 31Sale130.7221,1982,771,0038,649Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Option Exercise18.2743,802800,07752,451Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Sale130.0043,8025,694,2608,649Feb 01 08:24 PM